DUBLIN, May 11, 2023 /PRNewswire/ -- The "Global Central Nervous System Partnering 2016-2023: Deal trends, players and financials" report has been added to
ResearchAndMarkets.com's offering.
Global Central Nervous System Partnering 2016 to 2010 provides the full collection of central nervous system disease deals signed between the world's pharmaceutical and biotechnology companies since 2016.
Trends in central nervous system partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Central Nervous System partnering agreement structure
Central Nervous System partnering contract documents
Top central nervous system deals by value
Most active central nervous system dealmakers
Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.
The report takes readers through the comprehensive central nervous system disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering central nervous system deals.
The report presents financial deal terms values for central nervous system deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.
The initial chapters of this report provide an orientation of central nervous system dealmaking trends.
Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in central nervous system dealmaking since 2016 covering trends by year, deal type, stage of development, technology type and therapeutic indication.
Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.
Chapter 4 provides a review of the leading central nervous system deals since 2016. Deals are listed by headline value. The chapter includes the top 25 most active central nervous system dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 5 provides comprehensive access to central nervous system deals since 2016 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all central nervous system partnering deals by specific central nervous system target announced since 2016. The chapter is organized by specific central nervous system therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all central nervous system partnering deals signed and announced since 2016. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in central nervous system partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of central nervous system technologies and products.
Report scope
Global Central Nervous System Partnering 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to central nervous system trends and structure of deals entered into by leading companies worldwide.
Global Central Nervous System Partnering 2016 to 2023 includes:
Trends in central nervous system dealmaking in the biopharma industry since 2016
Access to headline, upfront, milestone and royalty data
Access to hundreds of central nervous system deal contract documents
Comprehensive access to over 1,700 central nervous system deal records
The leading central nervous system deals by value since 2016
Most active central nervous system dealmakers since 2016
The report includes deals for the following indications: Cerebral palsy, Creutzfeldt Jakob disease, Dizziness, Epilepsy, Faints, Falls, Guillain Barre syndrome, Headache, Meningitis (Bacterial, Meningococcal, Pneumococcal), Mycobacterium tuberculosis (TB), Haemophilus influenzae Type B (Hib), Migraine, Motor Neurone Disease (Amyotrophic Lateral Sclerosis/Lou Gehrig's Disease, Multiple sclerosis, Nausea, Neuropathy, Pain, Neuralgia, Fibromyalgia, Paralysis, Parkinson's disease, Restless leg syndrome, Spinal cord, Stroke, Stuttering, Traumatic Brain Injury, Vertigo, Weakness, plus other CNS indications.
In Global Central Nervous System Partnering 2016 to 2023, available deals and contracts are listed by:
Headline value
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Technology type
Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Central Nervous System Partnering 2016-2023 report provides comprehensive access to available deals and contract documents for over 1,700 central nervous system deals.
Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How are the sales and payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Selection of Companies Mentioned
1ST Biotherapeutics
2M
3M Drug Delivery Systems
3PrimeDx
3SBio
4SC Discovery
7D Surgical
23andMe
A&B Company
A*STAR Agency for Science
Technology and Research
Aarhus University Hospital
Abbott Laboratories
Abbvie
AbCellera
Abeona Therapeutics
Abide Therapeutics
Ablynx
Ab Medica
Abzena
ACADIA Pharmaceuticals
Accelerated Cure Project for MS
Accelovance
Accera Pharmaceuticals
Acella Pharmaceuticals
Acerus
Acetylon Pharmaceuticals
AC Immune
Acorda Therapeutics
Actavis (acquired by Watson)
Actelion
Acticor Biotech
Acturum Life
Acura Pharmaceuticals
AcuraStem
AdAlta
Adamas Pharmaceuticals
Adaptive Health
Adare Pharmaceuticals
Addex Therapeutics
Adept Neuro
Advanced Cooling Therapy
Advanced Technologies Solutions
Advantage Consumer Healthcare
Adventus Ventures
Aeon Bioscience
Aequus Pharmaceuticals
Aeromics
AEterna Zentaris
Aethlon Medical
Affilogic
AFFiRiS
Afraxis
AFT Pharmaceuticals
AgeX Therapeutics
Agilent Technologies
Agilis Biotherapeutics
Aguettant
Aiforia Technologies
AiPing Pharmaceutical
AirWare Labs
AKC Canine Health Foundation
Akorn
Akrimax Pharmaceutical
Albany Molecular Research
Alberta Health Services
Albert Einstein College of Medicine
Alcyone Lifesciences
Alder Biopharmaceuticals
Alector
Aleva Neurotherapeutics
Alexion Pharmaceuticals
Alfa Wassermann
AliveGen
Alkahest
Alkermes
Allen Institute for Brain Science
Allergan
Allergan (name changed from Actavis)
Allied Healthcare Products
Alnylam Pharmaceuticals
ALS Association
Alseres Pharmaceuticals
ALS Finding a Cure Foundation
Altair
Altus Formulation
AlzeCure Pharma
Alzheimer's Association
Alzheimer's Drug Discovery Foundation
Alzheimers Research UK
Amarantus BioSciences
Ambu
Amedica
Amendia
American Academy of Neurology
American Association of Neuromuscular & Electrodiagnostic Medicine
American College of Emergency Physicians
American College of Physicians Foundation
American Heart/Stroke Association
American Heart Association
American Migraine Foundation
American National Multiple Sclerosis Society
American Parkinson Diseases Association
American Speech-Language-Hearing Association
Amgen
Amicus Therapeutics
Amneal Pharmaceuticals
AmorChem
Amydis Diagnostics
Amylgen
AnaBios
Analytical Testing Laboratory
Anavex Life Sciences
ANI Pharmaceuticals
Annette Funicello Research Fund for Neurological Diseases (AFRFND)
Annovis Bio
AnthroTronix
Antibe Therapeutics
Antidote
Aphios
ApiFix
Appello Pharmaceuticals
AppliedVR
APR Applied Pharma Research
APRINOIA Therapeutics
Aptahem
Aptinyx
Aquinnah Pharmaceuticals
Aralez Pharmaceuticals
Aratana Therapeutics
arGEN-X
Arizona State University
ArmaGen
Array Biopharma
Arteaus Therapeutics
Artelo Biosciences
Arterys
Arvelle Therapeutics
Asahi Kasei
Asana Biosciences
Ascend Therapeutics
Asceneuron
AskAt
Asklepios Biopharmaceutical
Aspen Holding
Assertio Therapeutics
Association for Frontotemporal Degeneration
Astellas Pharma
Astellas Pharma Europe
Asterias Biotherapeutics
Astex Pharmaceuticals
AstraZeneca
ATAI Life Sciences
Atara Biotherapeutics
Ataxion
Athersys
Atnahs Pharma
Aucta Pharmaceuticals
Aural Analytics
Aurora Cannabis
Austin Health
Australian Imaging
Biomarker & Lifestyle Flagship Study of Ageing (AIBL)
Australian Research Council
Avanos Medical
Avella
Avenue Therapeutics
AveXis
AXIM Biotechnologies
AxoSim
Axovant Sciences
Axsome Therapeutics
Axxess Pharma
Aziyo Biologics
Bachem
Bachmann-Strauss Dystonia & Parkinson Foundation
Baergic Bio
Bain Capital
Banyan Biomarkers
Baudry Laboratory
Baxter International
Bayer
Baylor College
Baylor College of Medicine
B Braun
BD Consultancy
Becton Dickinson
Beijing Leadman Biochemistry
Ben-Gurion University
BenevolentAI
Benvenue Medical
Berg
Best Choice
Beyond Batten Disease Foundation
Bhang
Bial
BIA Separations
Biedermann Motech
Bio-Techne
BioArctic Neuroscience
biOasis Technologies
BioAxone Therapeutic
Biocodex
BIOCORP
BioCrossroads
Biodextris
Biodirection
Biofourmis
Biogen
Biohaven Pharmaceutical Holding
Biohealth Innovation
Bioinn Molecular Diagnosis
BioLamina
BiolineRX
BioMarin Pharmaceutical
Biomedical Advanced Research and Development Authority
BioMedical Research
BioMed X Innovation Center
BioMotiv
Bionik Laboratories
Bionomics
Bionure
Biopharmaceuticals Australia
BioQ Pharma
Bioscience Pharma Partners
BioSpring
BioSyent Pharma
BioTie Therapies
Biotoscana Farma
Biscayne Neurotherapeutics
Blackfynn
Blackrock Microsystems
Blackrock NeuroMed
BlackThorn Therapeutics
Blinktbi
Bloom Science
BlueRock Therapeutics
Boehringer Ingelheim
Boston Scientific
Boston University
Boston University School of Medicine
Bpifrance
Bracket
Braeburn Pharmaceuticals
Brain and Spine Institute
BRAINBox Solutions
BRAIN Initiative
BrainLAB
BrainScope
BrainStorm Cell Therapeutics
Brainsway
Brain Treatment Center San Diego
Brammer Bio
Breathe Active
BridgeBio Pharma
Brigham and Women's Hospital
Bristol-Myers Squibb
Broad Institute
Brooks Automation
Brown University
Bruker
C2N Diagnostics
C4 Therapeutics
C4X Discovery
Cactus Semiconductor
Cadence Biomedical
Cadence Pharmaceuticals
Cadila Pharmaceuticals
Cal-BRAIN
Calico
California Institute for Biomedical Research
California Institute for Regenerative Medicine
California Institute of Technology
Calmare Therapeutics
Calox de Costa Rica
Camargo Pharmaceutical Services
Camarus
Cambridge Cognition
Cambridge Commodities
Camino Partnership
CAMP4 Therapeutics
Canadian Institutes of Health Research
Canadian Physiotherapy Association
Canbex Therapeutics
Canigma
CannaKids
CannaRoyalty
Cellectricon
Celltrion
Cellular Dynamics International
Cellvation
Censo Biotechnologies
Center for iPS Cells Research and Application
Center for Sensorimotor Neural Engineering
Center for Technology and Innovation in Pediatrics (CTIP)
Center for the Advancement of Science in Space
Centinel Spine
Centogene
Centre for Commercialization of Regenerative Medicine (CCRM)
Centre for Drug Research and Development (CDRD)
Centre Hospital University - Bordeaux
Centrexion
Centro de Investigacion Biomedica en Red de Salud Mental
Century Medical
CerebraCell
Cerebral Therapeutics
Cerecor
CereHealth
Cerevel Therapeutics
CerSci Therapeutics
Certainty Health
Cerveau Technologies
Cervel Neurotech
Champalimaud Foundation
Chaperone Technologies
Charcot-Marie-Tooth Association
Charles River Associates
Charles River Laboratories
Charleston Laboratories
ChemDiv
ChemoCentryx
Children's Hospital Boston
Children's Hospital of Pittsburgh Foundation
Children's Hospital Of Wisconsin
Children's Minnesota
Children's Research Institute
ChoiceSpine
Christie Medical
Christopher & Dana Reeve Foundation
Chromocell
Chronos Therapeutics
Chugai Pharmaceutical
Cincinnati Children's Hospital Medical Center
Cipher Pharmaceuticals
Cipla Medpro
Circuit Therapeutics
Citizens United for Research in Epilepsy
City of Hope
Clene Nanomedicine
Cleveland Clinic
Cleveland Diabetes Care
Clevexel Pharma
Clinatec
Clinical Ink
Clinical Laserthermia Systems (CLS)
Clinical Network Services
Clinigen
Clinipace Worldwide
Clinvest
Cloud Pharmaceuticals
CluePoints
Cobra Biologics
Cofactor Genomics
Cognition Therapeutics
CogState
Cohen Veterans Bioscience
Colby College
Colgate University
Collegium Pharmaceuticals
Colorado HealthOP
Columbia University
Columbia University Medical Center
CombiGene
Compassionate Care Center of New York
Compass Point Research
Complement Pharma
Compumedics
Concordia Healthcare
Confo Therapeutics
Congenica
Congressman Chaka Fattah
Context Therapeutics
Convelo Therapeutics
Convergence Pharmaceuticals
Cook Biotech
Corbin Therapeutics
Corestem
Corium International
Coronado Biosciences
Corsair Innovations
CorTechs Labs
Cortexyme
Corvida Medical
Courtagen Life Sciences
Covis Pharmaceutical
Cranford Pharmaceuticals
CRC Health
Creatori Health
CRISPR Therapeutics
Cronos Group
Crossbeta Biosciences
Crown Laboratories
CSPC Pharmaceutical Group
Cumberland Pharmaceuticals
CURE Pharmaceutical
Dekel Pharmaceuticals
Denali Therapeutics
Denovo Biopharma
Department of Defense
Department of Health and Human Services
Department of Veterans Affairs
DepoMed
DePuy
DiaMedica
DiamiR
Dicerna Pharmaceuticals
Diego Pellicer
Dixi
DJO Global
DKSH
Doctor's Medical
Domain Therapeutics
Dong-A Pharmaceutical
Dr. Reddy's Laboratories
Dr. Stephen Cook
Draeger Safety Diagnostics
DrChrono
DuChemBio
Duke-NUS Graduate Medical School Singapore
Duke University
Durect
DyNAbind
Dystonia Europe
DZNE German Center for Neurodegenerative Diseases
E-Scape Bio
E-Therapeutics
Eagle Pharmaceuticals
Early Signal Foundation
Eastar Industries
ECM Therapeutics
EDAP TMS
Edge Therapeutics
Editas Medicine
Edith Cowan University (ECU)
eemagine
Egalet
EicOsis
Eisai
Eisai Inc
Ekso Bonics
ELC Group
Electrical Geodesics
ElectroCore
Elekta
Eli Lilly
Elite Pharmaceuticals
ElMindA
Ember Therapeutics
EMD Serono
EMMAC Life Sciences
Emory University
Empatica
EMS
Emulate
Enamine
Encoded Therapeutics
Endo International
Endonovo Therapeutics
Endo Pharmaceuticals
Endotronix
eNeura Therapeutics
Enigma Biomedical
Entia Biosciences
Epic Pharmaceuticals
Epilepsy Foundation (EF)
Epilepsy Society
Essex Bio-Technology
Esteve
Eton Pharmaceuticals
Eureka Eurostars
Euroimmun
European Commission
European Parkinson's Disease Association
European Union
Evidation Health
Evogen
Evotec
Ewopharma
Exactech
Exeltis
Exosome Sciences
Expesicor
Ezose Sciences
F-Star
FAAH Pharma
Fast Forward
FastFunds Financial
Federal Ministry of Education and Research (BMBF)
Feinstein Institute for Medical Research
Ferring Pharmaceuticals
FightMND
Firsthand Technology
Fitabase
FitBit
Flexion Therapeutics
Flint Rehabilitation Devices
Florey Institute of Neuroscience and Mental Heath
Florida Atlantic University Research
Flowonix
Flywheel
Fondazione Telethon
Food and Drug Administration (FDA)
Forbius
Forest Pharmaceuticals
FORMA Therapeutics
Fortress Biotech
Forward Pharma
Fosun Pharmaceutical
Foundation For Angelman Syndrome Therapeutics
Foundation for Mitochondrial Medicine
Foundation for the National Institutes of Health (FNIH)
Fresenius Kabi Pharmaceuticals
Fritz Clinic
FSD Pharma
Fudan University
Fukuda Denshi
Fundacion Universidad Torcuato Di Tella
Fuzionaire Diagnostics
Gain Therapeutics
Galapagos
Galen
Galena Biopharma
GB Sciences
GE Healthcare
Geisinger Medical Center
Genea Biocells
GeneData
Genentech
General Electric (GE)
Gene Therapy Research Institution
Genethon
GeNeuro
Genmab
Genomics
Genomind
Genzyme
Geo-Med
George Washington University
Georgia Institute of Technology
Gestion Univalor
Gilead Sciences
Ginkgo BioWorks
GlaxoSmithKline
Glialogix
Global Alliance for Innovation in Neuroscience
Global Drug Development Centre (GDCC) China
Global Kinetics
GM Medical
GNS Healthcare
Gold Coast Therapeutics
Golden Meditech
Goodwin Biotechnology
Google
And More
For more information about this report visit
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Media Contact:
Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Logo -
SOURCE Research and Markets